

Supplementary information

Discrepancies between high-resolution native and glycopeptide-centric mass spectrometric approaches: A case study into the glycosylation of erythropoietin variants

Tomislav Čaval^{1,2,*}, Alexander Buettner³, Markus Habberger³, Dietmar Reusch³, Albert J.R. Heck^{1,2,#}

¹Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, Utrecht, 3584 CH, The Netherlands

²Netherlands Proteomics Center, Padualaan 8, Utrecht, 3584 CH, The Netherlands

³Pharma Technical Development, Roche Diagnostics GmbH, Penzberg 82377, Germany

[#]Corresponding author




Figure S1. Upsized spectrum of EPO-1) Native MS spectrum of non-sialidase treated EPO-1. Each peak is color coded and represents a unique $\text{Hex}_{x+3}\text{HexNAc}_x\text{F}_3$ composition where the numbers above the color codes indicate the cumulative number of sialic acid residues attached to the EPO glycans.